MKI67 and ductal breast carcinoma in situ: Subsequent histological analysis of the tumor xenografts showed decreased Ki67 expression in the center of xenografts formed by NLR-JIMT co-injected with cancer patient-derived MSC-BRCA+, MSC-DCIS and MSC-CA than in NLR-JIMT co-injected with healthy donor-derived MSC-H, or NLR-JIMT alone (Figure 8C, 1st column).